Roles of Cytochrome P-450 Enzymes in Chemical Carcinogenesis and Cancer Chemotherapy

Cancer Research

Volumn 48, Issue 11, 1986, Pages 2946-2954

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

CHEMICAL CARCINOGENESIS; NONHUMAN; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; HUMAN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023951396     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (132)

1. Mueller, G. C., and Miller, J. A. The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J. Biol. Chem., 176:535-544, 1948.
2. Mueller, G. C., and Miller, J. A. The metabolism of methylated aminoazo dyes. II. Oxidative demethylation by rat liver homogenates. J. Biol. Chem., 202:579-587,1953.
3. Omura, T., and Sato, R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem., 239: 2370-2378,1964.
4. Cooper, D. Y., Levine, S., Narasimhulu, S., Rosenthal, O., and Estabrook, R. W. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science (Wash. DC), 147:400-402, 1965.
5. Brown, R. R., Miller, J. A., and Miller, E. C. The metabolism of methylated amino azo dyes. IV. Dietary factors enhancing demethylation in vitro. J. Biol. Chem., 209:211-222,1954.
6. Conney, A. H., Miller, E. C., and Miller, J. A. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methykholanthrene. Cancer Res., 16:450-459,1956.
7. Remmer, H. The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol., 237:296-307, 1957.
8. Sladek, N. E., and Mannering, G. J. Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene-treated rats. Biochem. Biophys. Res. Commun., 24:668-674,1966.
9. Alvares, A. P., Schilling, G., Levin, W., and Kuntzman, R. Studies in the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. Biochem. Biophys. Res. Commun., 29: 521–526, 1967.
10. Guengerich, F. P. Enzymology of rat liver cytochromes P-450. In: F. P. Guengerich (ed.), Mammalian Cytochromes P-450, Vol. 1, pp. 1–54. Boca Raton, FL: CRC Press, 1987.
11. Distlerath, L. M., and Guengerich, F. P. Enzymology of human liver cytochromes P-450. In: F. P. Guengerich (ed.), Mammalian Cytochromes P-450, Vol. 1, pp. 133–198. Boca Raton, FL: CRC Press, 1987.
12. Guengerich, F. P. Cytochrome P-450 enzymes and drug metabolism. In: J. Bridges, L. F. Chasseaud, and G. G. Gibson (eds.), Progress in Drug Metabolism, Vol. 10, Chap. 1, pp. 1–54. London: Taylor and Francis, 1987.
13. Nebert, D. W., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I. R., Sato, R., and Waterman, M. R. The P-450 gene superfamily. Recommended nomenclature. DNA, 6:1-11,1987.
14. 1and benzo(a)pyrene. J. Biol. Chem., 259:12495-12501,1984.
15. Ortiz de Montellano, P. R. Cytochrome P-450: Structure, Function, and Mechanism. New York: Plenum Publishing Corp., 1986.
16. Whitlock, J. P., Jr. The regulation of cytochrome P-450 gene expression. Annu. Rev. Pharmacol. Toxicol., 26:333-369,1986.
17. Guengerich, F. P. (ed.). Mammalian Cytochromes P-450, Vols. 1 and 2. Boca Raton, FL: CRC Press, 1987.
18. Nebert, D. W., and Gonzalez, F. J. P-450 genes: structure, evolution, and regulation. Annu. Rev. Biochem., 56:945-993,1987.
19. Kadlubar, F. F., and Hammons, G. J. Role of cytochrome P-450 in metabolism of chemical carcinogens. In: F. P. Guengerich (ed.), Mammalian Cytochromes P-450, Vol. 2, pp. 81–130. Boca Raton, FL: CRC Press, 1987.
20. Searle, C. E. (ed.). Chemical Carcinogens, Ed. 2. ACS Monograph 182, Vols. 1 and 2. Washington, DC: American Chemical Society, 1984.
21. Nebert, D. W. Genetic control of carcinogen metabolism leading to individual differences in cancer risk. Biochimie (Paris), 60:1019-1029,1978.
22. Boyd, M. R. Effects of inducers and inhibitors on drug-metabolizing enzymes and on drug toxicity in extrahepatic tissues. In: Excerpta Medica, Environmental Chemicals, Enzyme Function, and Human Diseases (CIBA Foundation Symposium 76), pp. 43–76. Basel, Switzerland: Excerpta Medica. 1980.
23. Weisburger, E. K. Metabolism and activation of chemical carcinogens. Mol. Cell. Biochem., 32:95-104, 1980.
24. Wright, A. S. The role of metabolism in chemical mutagenesis and chemical carcinogenesis. Mutat. Res., 75: 215–241, 1980.
25. Farber, E. Chemical carcinogenesis. N. Engl. J. Med., 305: 1379–1389, 1981.
26. Miller, E. C., and Miller, J. A. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer (Phila.), 47:2327-2345, 1981.
27. Weinstein, I. B. Current concepts and controversies in chemical carcinogenesis. J. Supramol. Struct. Cell. Biochem., 17:99-120, 1981.
28. Conney, A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res., 42:4875-4917,1982.
29. Weisburger, J. H., and Williams, G. M. Metabolism of chemical carcinogens. In: F. F. Becker (ed.), Cancer A Comprehensive Treatise, Vol. 1, Ed. 2, pp. 241–333. New York: Plenum Publishing Corp., 1982.
30. Dipple, A., Michejda, C. J., and Weisburger, E. K. Metabolism of chemical carcinogens. Pharmacol. Ther., 27: 265-296,1985.
31. Kato, R. Metabolic activation of mutagenic heterocyclic aromatic amines from protein pyrolysates. CRC Crit. Rev. Toxicol., 16:307-348, 1986.
32. Schwab, G. E., and Johnson, E. F. Enzymology of rabbit cytochromes P-450. In: F. P. Guengerich (ed.), Mammalian Cytochromes P-450, Vol. 1, pp. 55–105, Boca Raton, FL: CRC Press, 1987.
33. Shimada, T., and Nakamura, S.-I. Cytochrome P-450-mediated activation of procarcinogens and promutagens to DNA-damaging products by measuring expression of umu gene in Salmonella typhimurium TA1535/pSK 1002. Biochem. Pharmacol., 36:1979-1987,1987.
34. Guengerich, F. P. Separation and purification of multiple forms of microsomal cytochrome P-450. Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J. Biol. Chem., 252: 3970-3979,1977.
35. 1 Carcinogenesis (Lond.), 4:93-96,1983.
36. 1by several forms of purified cytochrome P-450. Mutat. Res., 774:85-88, 1986.
37. 1by constitutive forms of cytochrome P-450 in rat liver microsomes. Toxicol. Appl. Pharmacol., 91:13-21,1987.
38. Kawano, S., Kamataki, T., Maeda, K., Kato, R., Nakao, T., and Mizoguchi, I. Activation and inactivation of a variety of mutagenic compounds by the reconstituted system containing highly purified preparations of cytochrome P-450 from rat liver. Fundam. Appl. Toxicol., 5: 487-498,1985.
39. Guengerich, F. P., Butler, M. A., Macdonald, T. L., and Kadlubar, F. F. Oxidation of carcinogenic aryl amines by cytochrome P-450 enzymes. In: C. M. King, L. J. Romano, and D. Schuetzle (eds.), Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes, pp. 89–95. New York: Elsevier Scientific Publishing Co., Inc., 1987.
40. Frederick, C. B., Mays, J. B., Ziegler, D. M., Guengerich, F. P., and Kadlubar, F. F. Cytochrome P-450 and flavin-containing monooxygenase-catalyzed formation of the carcinogen N-hydroxy-2-aminofluorene, and its covalent binding to nuclear DNA. Cancer Res., 42:2671-2677,1982.
41. Hammons, G. J., Guengerich, F. P., Weis, C. C., Beland, F. A., and Kadlubar, F. F. Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases. Cancer Res., 45:3578-3585, 1985.
42. Wood, A. W., Levin, W., Lu, A. Y. H., Yagi, H., Hernandez, O., Jerina, D. M., and Conney, A. H. Metabolism of benzo(a)pyrene and benzo(a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J. Biol. Chem., 251:4882-4890, 1976.
43. 5Arch. Biochem. Biophys., 248:158-165,1986.
44. s. Arch. Biochem. Biophys., 251:629-638, 1986.
45. Yamazoe, Y., Shimada, M., Maeda, K., Kamataki, T., and Kato, R. Specificity of four forms of cytochrome P-450 in the metabolic activation of several aromatic amines and benzo(a)pyrene. Xenobiotica, 14: 549–552, 1984.
46. Kimura, T., Kodama, M., Nagata, C., Kamataki, T., and Kato, R. Comparative study on the metabolism of N-methyl-4-aminoazobenzene by two forms of cytochrome P-448. Biochem. Pharmacol., 34:3375-3377, 1985.
47. Shimada, T., and Guengerich, F. P. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16a-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin. Mol. Pharmacol., 28:215-219,1985.
48. Beaune, P., Kremers, P. G., Kaminsky, L. S., De Graeve, J., and Guengerich, F. P. Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab. Dispos., 74:437-442, 1986.
49. Kaminsky, L. S., Guengerich, F. P., Dannan, G. A., and Aust, S. D. Comparisons of warfarin metabolism by liver microsomes of rats treated with a series of polybrominated biphenyl congeners and by the component-purified cytochrome P-450 isozymes. Arch. Biochem. Biophys., 225: 398-404,1983.
50. Guengerich, F. P., Martin, M. W., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261: 5051-5060,1986.
51. Kaminsky, L. S., and Guengerich, F. P. Cytochrome P-450 isozyme/ isozyme functional interactions and NADPH-cytochrome P-450 reductase concentrations as factors in microsomal metabolism of warfarin. Eur. J. Biochem., 149:479-489,1985.
52. Zuber, M. X., Simpson, E. R., and Waterman, M. R. Expression of bovine 17a-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science (Wash. DC), 234:1258-1261,1986.
53. Hall, S. D., Guengerich, F. P., Branch, R. A., and Wilkinson, G. R. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther., 240:216-222,1987.
54. Ortiz de Montellano, P. R., and Correia, M. A. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu. Rev. Pharmacol. Toxicol., 23:481-503,1983.
55. Fujino, T., Park, S. S., West, D., and Gelboin, H. V. Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 79:3682-3686, 1982.
56. Distlerath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin 0-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 260:9057-9067,1985.
57. Kaminsky, L. S., Dannan, G. A., and Guengerich, F. P. Composition of cytochrome P-450 isozymes from hepatic microsomes of C57BL/6 and DBA/2 mice assessed by warfarin metabolism, immunoinhibition, and immunoelectrophoresis with anti-(rat cytochrome P-450). Eur. J. Biochem., 747:141-148,1984.
58. Guengerich, F. P. Preparation and properties of highly-purified cytochrome P-450 and NADPH-cytochrome P-450 reductase from pulmonary microsomes of untreated rabbits. Mol. Pharmacol., 13:911-923,1977.
59. Guengerich, F. P. Separation and purification of multiple forms of microsomal cytochrome P-450. Partial characterization of three apparently homogeneous cytochromes P-450 prepared from livers of phenobarbital- and 3-methylcholanthrene-treated rats. J. Biol. Chem., 253:7931-7939,1978.
60. Umbenhauer, D. R., Martin, M. V., Lloyd, R. S., and Guengerich, F. P. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry, 26:1094-1099,1987.
61. Levitt, R. C., Pelkonen, O., Okey, A. B., and Nebert, D. W. Genetic differences in metabolism of polycyclic aromatic carcinogens and aromatic amines by mouse liver microsomes. Detection by DNA binding of metabolites and by mutagenicity in histidine-dependent Salmonella typhimurium in vitro. J. Natl. Cancer Inst., 62:947-955,1979.
62. Nebert, D. W., Atlas, S. A., Guenthner, T. M., and Kouri, R. E. The Ah locus: genetic regulation of the enzymes which metabolize polycyclic hydrocarbons and the risk for cancer. In: P. O. P. Ts'o and H. V. Gelboin (eds.), Polycyclic Hydrocarbons and Cancer: Chemistry, Molecular Biology and Environment, Vol. 2, pp. 345–390. New York: Academic Press, 1978.
63. Levitt, R. C., Fysh, J. M., Jensen, N. M., and Nebert, D. W. The Ah locus: biochemical basis for genetic differences in brain tumor formation in mice. Genetics, 92:1205-1210,1979.
64. Nebert, D. W. Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia. Environ. Health Perspect., 39:11-22,1981.
65. Kouri, R. E., Rude, T. H., Joglekar, R., Dansette, P. M., Jerina, D. M., Atlas, S. A., Owens, I. S., and Nebert, D. W. 2,3,7,8-Tetrachlorodibenzo-p-dioxin: cocarcinogen which enhances 3-methylcholanthrene-initiated subcutaneous tumors in mice genetically “nonresponsive” at Ah locus. Cancer Res., 38:2777-2783,1978.
66. Poland, A., Palen, D., and Glover, E. Tumour production by TCDD in skin of HRS/J hairless mice. Nature (Lond.), 300:217-273,1982.
67. McLean, A. E. M., and Marshall, A. Reduced carcinogenic effects of aflatoxin in rats given phenobarbitone. Br. J. Exp. Pathol., 52: 322–329, 1971.
68. 2to rat liver DNA and ribosomal RNA in vivo. Cancer Res., 37: 172-181,1977.
69. Tawfic, H. N. Studies on ear duct tumors in rats. Part II: Inhibitory effects of methylcholanthrene and 1,2-benzanthracene on tumor formation by 4-dimethylaminostilbene. Acta Pathol. Jpn., 15:255-260,1965.
70. Kunz, W., Schande, G., and Thomas, C. The effect of phenobarbital and halogenated hydrocarbons on nitrosamine carcinogenesis. Z. Krebsforsch., 72:291-304,1969.
71. Uchida, E., and Hirono, I. Effect of phenobarbital on induction of liver and lung tumors by dimethylnitrosamine in newborn mice. Gann, 70:639-644, 1979.
72. Richardson, H. L., Stier, A. R., and Borsos-Nachtnebel, E. Liver tumor inhibition and adrenal histologic responses in rats to which 3'-methyl-4-dimethylaminoazobenzene and 20-methylcholanthrene were simultaneously administered. Cancer Res., 12:356-361,1952.
73. Miller, E. C., Miller, J. A., Brown, R. R., and MacDonald, J. C. On the protective action of certain polycyclic aromatic hydrocarbons against carcinogenesis by aminoazo dyes and 2-acetylaminofluorene. Cancer Res., 18: 469-477,1958.
74. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem., 257: 7847–7851, 1982.
75. Verma, A. K., Conrad, E. A., and Boutwell, R. K. Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenic process and by the initation-promotion regimen. Cancer Res., 42:3519-3525, 1982.
76. Verma, A. K., Garcia, C. T., Ashendel, C. L., and Boutwell, R. K. Inhibition of 7-bromoethylbenz(a)anthracene-promoted mouse skin tumor formation by retinoic acid and dexamethasone. Cancer Res., 43:3045-3049,1983.
77. Scribner, J. D., Scribner, N. K., McKnight, B., and Mottet, N. K. Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromoethylbenz(a)anthracene. Cancer Res., 43: 2034-2041,1983.
78. Boberg, E. W., Liem, A., Miller, E. C., and Miller, J. A. Inhibition by pentachlorophenol of the initiating and promoting activities of l'-hydrox-ysafrole for the formation of enzyme-altered foci and tumors in rat liver. Carcinogenesis (Lond.), 8:531-539,1987.
79. Kellermann, G., Luyten-Kellermann, M., and Shaw, C. R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet., 25:327-331,1973.
80. Kellermann, G., Shaw, C. R., and Luyten-Kellermann, M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med., 298:934-937,1973.
81. Paigen, B., Ward, E., Reilly, A., Gurtoo, H. L., Minowada, J., Steenland, K., Havens, M. B., and Sartori, P. Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res., 41: 2757–2761, 1981.
82. Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgress, D. R., Wray, N. P., and McLemore, T. L. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopre-served lymphocytes. Cancer Res., 42:5030-5037,1982.
83. 1-450 gene sequence and correlation of mRNA with genetic differences in benzo-(a)pyrene metabolism. Nucl. Acids Res., 13:4503-4520,1985.
84. Karki, N. T., Pokela, R., Nuutinen, L., and Pelkonen, O. Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. Int. J. Cancer, 39:565-570,1987.
85. De Flora, S., Petruzzelli, S., Camoirano, A., Bennicelli, C., Romano, M., Rindi, M., Ghelarducci, L., and Giuntini, C. Pulmonary metabolism of mutagens and its relationship with lung cancer and smoking habits. Cancer Res., 47:4740-4745,1987.
86. Idle, J. R., Mahgoub, A., Sloan, T. P., Smith, R. L., Mbanefo, C. O., and Bababunmi, E. A. Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Lett., 11:331-338,1981.
87. Wolff, T., Distlerath, L. M., Worthington, M. T., Groopman, J. D., Hammons, G. J., Kadlubar, F. F., Prough, R. A., Martin, M. V., and Guengerich, F. P. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res., 45:2116-2122,1985.
88. 1 catalyzed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man? Arch. Toxicol., 58:165-170,1986.
89. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312:169-170,1984.
90. Drakoulis, N., Minks, T., Ploch, M., Otte, F., Heinemeyer, G., Kampf, D., Loddenkemper, R., and Roots, I. Questionable association of debrisoquine hydroxilator [sic] phenotype and risk for bronchial carcinoma. Acta Pharmacol. Toxicol., 59 (Suppl. 5): 220,1986.
91. Harris, C. C., Weston, A., Willey, J. C., Trivers, G. E., and Mann, D. L. Biochemical and molecular epidemiology of human cancer indicators of carcinogen exposure, DNA damage, and genetic predisposition. In: D. J. Birkett (ed.), Microsomes and Drug Oxidations (Proceedings of the Seventh International Symposium). London: Taylor and Francis, in press, 1988.
92. Ritter, J., Somasundaram, R., Heinemeyer, G., and Roots, I. The debrisoquine hydroxilation [sic] phenotype and the acetylator phenotype as genetic risk factors for the occurrence of larynx and pharynx carcinoma. Acta Pharmacol. Toxicol., 59 (Suppl. 5): 221, 1986.
93. Kaisary, A., Smith, P., Jaczq, E., McAllister, C. B., Wilkinson, G. R., Ray, W. A., and Branch, R. A. Genetic predisposition to bladder cancer, ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47: 5488–5493, 1987.
94. Yang, C. S. Research on esophageal cancer in China: a review. Cancer Res., 40:2633-2644,1980.
95. Trzaskos, J., Kawata, S., and Gaylor, J. C. Microsomal enzymes of cholesterol biosynthesis: purification of lanosterol 14a-methyl demethylase cytochrome P-450 from hepatic microsomes. J. Biol. Chem., 261:14651-14657, 1986.
96. Kellis, J. T., Jr., and Vickery, L. E. Purification and characterization of human placental aromatase cytochrome P-450. J. Biol. Chem., 262:4413-4420,1987.
97. Graves, P. E., Kaminsky, L. S., and Halpert, J. Evidence for functional and structural multiplicity of pregnenolone- 16α-carbonitrile-inducible cytochrome P-450 isozymes in rat liver microsomes. Biochemistry, 26: 3887–3894, 1987.
98. Baron, J., Voigt, J. M., Whitter, T. B., Kawabata, T. T., Knapp, S. A., Guengerich, F. P., and Jakoby, W. B. Identification of intratissue sites for xenobiotic activation and detoxication. Adv. Exp. Med., 197:119-144. New York: Plenum Publishing Corp., 1986.
99. Kapitulnik, J., Wislocki, P. G., Levin, W., Yagi, H., Jerina, D. M., and Conney, A. H. Tumorigenicity studies with diol-epoxides of benzo[α]-pyrene which indicate that (+) trans-7β,8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tet-rahydrobenzo[a]pyrne is an ultimate carcinogen in newborn mice. Cancer Res., 38: 354-358,1978.
100. Guengerich, F. P., and Liebler, D. C. Enzymatic activation of chemicals to toxic metabolites. CRC Crit Rev. Toxicol., 14:259-307, 1985.
101. Hogy, L. L., and Guengerich, F. P. In vivo interaction of acrylonitrile and 2-cyanoethylene oxide with DNA in rats. Cancer Res., 46: 3932–3938, 1986.
102. Mattocks, A. R., and Driver, H. E. Metabolism and toxicity of anacrotine, a pyrrolizidine alkaloid, in rats. Chem.-Biol. Interact, 63:91-104,1987.
103. Kadlubar, F. F., Dooley, K. L., Benson, R. W., Roberts, D. W., Butler, M. A., Teitel, C. H., Bailey, J. R., and Young, J. F. Pharmacokinetic model of aromatic amine-induced urinary bladder carcinogenesis in beagle dogs administered 4-aminobiphenyl. In: C. M. King, L. J. Romano, and D. Schuetzle (eds.), Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes, pp. 173–180. New York: Elsevier Scientific Publishing Co., Inc., 1987.
104. Dannan, G. A., and Guengerich, F. P. Immunochemical comparison and quantitation of microsomal flavin-containing monooxygenases in various hog, mouse, rat, rabbit, dog, and human tissues. Mol. Pharmacol., 22:787-794, 1982.
105. Williams, D. E., Ziegler, D. M., Nordin, D. J., Hale, S. E., and Masters, B. S. S. Rabbit lung flavin-containing monooxygenase is immunochemically and catalytically distinct from the liver enzyme. Biochem. Biophys. Res. Commun., 125:116-122,1984.
106. Krauss, R. S., and Eling, T. E. Arachidonic acid-dependent cooxidation: a potential pathway for the activation of chemical carcinogens in vivo. Biochem. Pharmacol., 33:3319-3324,1984.
107. Battista, J. R., and Marnett, L. J. Prostaglandin H synthase-dependent epoxidation of aflatoxin B,. Carcinogenesis (Lond.), 6:1227-1229,1985.
108. Marnett, L. J. Arachidonic acid metabolism and tumor initiation. In: L. J. Marnett (ed.), Arachidonic Acid Metabolism and Tumor Initiation, pp. 39–82. The Hague: Martinus Nihoff Publishing, 1985.
109. Sakaki, T., Oeda, K., Miyoshi, M., and Ohkawa, H. Characterization of rat cytochrome p-450mc synthesized in Saccharomyces cerevisiae. J. Biochem. (Tokyo), 98:167-175,1985.
110. 4 from phenobarbital-treated rabbit liver: molecular cloning of cDNA and characterization of cytochrome P-450 obtained by its expression in yeast cells. J. Biochem. (Tokyo), 101: 1129-1139,1987.
111. Nagata, K., Matsunaga, T., Gillette, J., Gelboin, H. V., and Gonzalez, F. J. Rat testosterone 7a-hydroxylase: isolation, sequence, and expression of cDNA and its developmental regulation and induction by 3-methylcholanthrene. J. Biol. Chem., 262; 2787–2793, 1987.
112. Guengerich, F. P., Müler-Enoch, D., and Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 30:287-295,1986.
113. Knodell, R. G., Hall, S. D., Wilkinson, G. R., and Guengerich, F. P. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther., 241:1112-1119, 1987.
114. Miners, J. O., Robson, R. A., Smith, K. J., McManus, M. E., and Birkett, D. J. Relationship between tolbutamide hydroxylation and other cytochrome P-450 dependent oxidations in human liver microsomes. In: D. J. Birkett (ed.), Microsomes and Drug Oxidations (Seventh International Symposium). London: Taylor and Francis, in press, 1988.
115. Peterson, J. E. Modeling the uptake, metabolism, and excretion of dichlo-romethane by man. Am. Ind. Hyg. Assoc. J., 39:41-47,1978.
116. Buchter, A., Bolt, H. M., Filser, J. G., Goergens, H. W., Laib, R. J., and Bolt, W. Pharmakokinetik und Karzinogenese von Vinylchlorid. Verb. Dtsch. Ges. Arbeitsmed., 18:111-124,1978.
117. Straubinger, R. M., Hong, K., Friend, D. S., and Papahadjopoulos, D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell, 32:1069-1079,1983.
118. Docherty, P. A., and Aronson, N. N., Jr. Injection of proteins into primary rat hepatocytes by erythrocyte-mediated techniques. Biochem. Biophys. Res. Commun., 109:527-532,1982.
119. McElligott, M. A., and Dice, J. F. Erythrocyte-mediated microinjection, a technique to study protein degradation in muscle cells. Biochem. J., 216: 559-566,1983.
120. Goldsworthy, T. L., Hanigan, M. H., and Pitot, H. C. Models of hepato-carcinogenesis in the rat-contrasts and comparisons. CRC Crit. Rev. Toxicol., 17:61-89, 1986.
121. Cline, M. J., and Haskell, C. M. Factors affecting the usefulness of drugs. Cancer Chemotherapy, Ed. 3, Chap. 2, pp. 13–30. Philadelphia: W. B. Saunders Co., 1980.
122. Erlichman, C., and Kerr, I. G. Antineoplastic drugs. In: H. Kant, W. H. E. Roschlau, and E. M. Sellers (eds.), Principles of Medical Pharmacology, Ed. 4, Chap. 59, pp. 699–710. Toronto, Canada: University of Toronto Press, 1985.
123. El Mouelhi, M., Didolkar, M. S., Elias, E. G., Guengerich, F. P., and Kauffman, F. C. Hepatic drug metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res., 47:460-466,1987.
124. Kennedy, K. A., Teicher, B. A., Rockwell, S., and Sartorelli, A. C. Chemotherapeutic approaches to cell populations of tumors. In: A. C. Sartorelli, J. S. Lazo, and J. R. Bertino (eds.), Molecular Actions and Targets for Cancer Chemotherapeutic Agents, Bristol Myers Cancer Symposium 3, pp. 85–101. New York: Academic Press, 1981.
125. Marinello, A. J., Bansal, S. K., Paul, B., Koser, P. L., Love, J., Struck, R. F., and Gurtoo, H. L. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450. Cancer Res., 44:4615-4621,1984.
126. Struck, R. F., Kari, P., Kalin, J., Montgomery, J. A., Marinello, A. J., Love, J., Bansal, S. K., and Gurtoo, H. L. Metabolism of cyclophosphamide by purified cytochrome P-450 from microsomes of phenobarbital-treated rats. Biochem. Biophys. Res. Commun., 120:390-396,1984.
127. Prough, R. A., Brown, M. I., Dannan, G. A., and Guengerich, F. P. Major isozymes of rat liver microsomal cytochrome P-450 involved in the N-oxidation of N-isopropyl-α-(2-methylazo)-p-toluamide, the azo derivative of procarbazine. Cancer Res., 44:543-548,1984.
128. Potter, D. W., Levin, W., Ryan, D. E., Thomas, P. E., and Reed, D. J. Stereoselective monooxygenation of carcinostatic l-(2-chloroethyl)-3-(cy-clohexyl)-1 -nitrosourea and l-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea by purified cytochrome P-450 isozymes. Biochem. Pharmacol., 55:609-613,1984.
129. Cowan, K. H., Batist, G., Tulpule, A., Sinha, B. K., and Myers, C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. USA, 83:9328-9332,1986.
130. Carr, B. I. Pleiotropic drug resistance in hepatocytes induced by carcinogens administered to rats. Cancer Res., 47:5577-5583, 1987.
131. Colvin, M., and Grochow, L. B. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 4:380-394,1979.
132. Shimada, T., Misono, K. S., and Guengerich, F. P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism: purification and characterization of two similar forms involved in the reaction. J. Biol. Chem., 261: 909–921, 1986.